Harrow Eye patents expiration
1. Iheezo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792271 | HARROW EYE | Topical formulations of chloroprocaine and methods of using same |
Sep, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 27, 2025 |
Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 September, 2022
Treatment: Method of inducing ocular anesthesia
Dosage: GEL;OPHTHALMIC
IHEEZO family patents
2. Ilevro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5475034 | HARROW EYE | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
Jun, 2014
(9 years ago) | |
| US6403609 | HARROW EYE | Ophthalmic compositions containing galactomannan polymers and borate |
Jul, 2018
(5 years ago) | |
| US7947295 | HARROW EYE | Ophthalmic compositions containing a synergistic combination of two polymers |
Jun, 2024
(a month from now) | |
| US9662398 | HARROW EYE | Carboxylvinyl polymer-containing nanoparticle suspensions |
Dec, 2030
(6 years from now) | |
| US8921337 | HARROW EYE | Carboxyvinyl polymer-containing nanoparticle suspensions |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 16, 2015 |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 16 October, 2012
Treatment: Method of treating ocular inflammation
Dosage: SUSPENSION/DROPS;OPHTHALMIC
ILEVRO family patents
3. Moxeza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5607942 | HARROW EYE | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5607942 (Pediatric) | HARROW EYE | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Sep, 2014
(9 years ago) | |
| US6716830 | HARROW EYE | Ophthalmic antibiotic compositions containing moxifloxacin |
Sep, 2019
(4 years ago) | |
| US7671070 | HARROW EYE | Method of treating ophthalmic infections with moxifloxacin compositions |
Sep, 2019
(4 years ago) | |
|
US6716830 (Pediatric) | HARROW EYE | Ophthalmic antibiotic compositions containing moxifloxacin |
Mar, 2020
(4 years ago) | |
|
US7671070 (Pediatric) | HARROW EYE | Method of treating ophthalmic infections with moxifloxacin compositions |
Mar, 2020
(4 years ago) | |
| US8450311 | HARROW EYE | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(5 years from now) | |
| US9114168 | HARROW EYE | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 19, 2013 |
| Pediatric Exclusivity(PED) | May 19, 2014 |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 19 November, 2010
Treatment: Method of combating bacteria in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
MOXEZA family patents
4. Nevanac patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5475034 | HARROW EYE | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
Jun, 2014
(9 years ago) | |
| US8324281 | HARROW EYE | Topical nepafenac formulations |
Dec, 2025
(1 year, 7 months from now) | |
| US8071648 | HARROW EYE | Topical nepafenac formulations |
Dec, 2025
(1 year, 7 months from now) | |
| US7834059 | HARROW EYE | Topical nepafenac formulations |
Jan, 2027
(2 years from now) | |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 19 August, 2005
Treatment: Method of treating ocular inflammation
Dosage: SUSPENSION/DROPS;OPHTHALMIC
NEVANAC family patents
5. Tobradex St patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8450287 | HARROW EYE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Dec, 2027
(3 years from now) | |
| US8101582 | HARROW EYE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Dec, 2027
(3 years from now) | |
| US7795316 | HARROW EYE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Aug, 2028
(4 years from now) | |
Drugs and Companies using DEXAMETHASONE; TOBRAMYCIN ingredient
Market Authorisation Date: 13 February, 2009
Treatment: Use of a combination of tobramycin and dexamethasone to treat ocular inflammation where an infection or risk of infection exists
Dosage: SUSPENSION/DROPS;OPHTHALMIC
TOBRADEX ST family patents
6. Triesence patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395294 | HARROW EYE | Method of visualization of the vitreous during vitrectomy |
Jan, 2020
(4 years ago) | |
| US8211880 | HARROW EYE | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Mar, 2029
(4 years from now) | |
| US8128960 | HARROW EYE | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Dec, 2029
(5 years from now) | |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 29 November, 2007
Treatment: Use for delineation (visualization) during a vitrectomy surgical procedure; Treatment of ophthalmic disorders
Dosage: INJECTABLE;INTRAVITREAL
TRIESENCE family patents
7. Verkazia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9220694 | HARROW EYE | Emulsion compositions containing cetalkonium chloride |
Jan, 2026
(1 year, 8 months from now) | |
| US7973081 | HARROW EYE | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(1 year, 8 months from now) | |
| US9956289 | HARROW EYE | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(1 year, 8 months from now) | |
| US11612658 | HARROW EYE | Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same |
Jan, 2026
(1 year, 8 months from now) | |
| US8524779 | HARROW EYE | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(1 year, 8 months from now) | |
| US8298568 | HARROW EYE | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
Nov, 2027
(3 years from now) | |
| US9132071 | HARROW EYE | Compositions containing quaternary ammonium compounds |
Jun, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-358) | Jun 23, 2028 |
| New Product(NP) | Jun 23, 2024 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 June, 2021
Treatment: For the treatment of vernal keratoconjunctivitis in children and adults
Dosage: EMULSION;OPHTHALMIC
VERKAZIA family patents
8. Vevye patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8614178 | HARROW EYE | Pharmaceutical composition for treatment of dry eye syndrome |
Dec, 2030
(6 years from now) | |
| US10813976 | HARROW EYE | Ophthalmic compositions comprising ciclosporin |
Sep, 2037
(13 years from now) | |
| US11154513 | HARROW EYE | Semifluorinated compounds |
Nov, 2038
(14 years from now) | |
| US11413323 | HARROW EYE | Ophthalmic composition for treatment of dry eye disease |
Oct, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2026 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 30 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of dry eye disease (ded)
Dosage: SOLUTION;OPHTHALMIC
VEVYE family patents
9. Zerviate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750684 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
| US8829005 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
| US9993471 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
|
US8829005 (Pediatric) | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Sep, 2030
(6 years from now) | |
| US9254286 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Jul, 2032
(8 years from now) | |
|
US9254286 (Pediatric) | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 30, 2020 |
| Pediatric Exclusivity(PED) | Nov 30, 2020 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2017
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
ZERVIATE family patents